- Home
- IMNM vs CELC Comparison
IMNM vs CELC Comparison
Compare IMNM & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- CELC
- Stock Information
- Founded
- IMNM 2006
- CELC 2011
- Country
- IMNM United States
- CELC United States
- Employees
- IMNM N/A
- CELC N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- CELC Medical Specialities
- Sector
- IMNM Health Care
- CELC Health Care
- Exchange
- IMNM Nasdaq
- CELC Nasdaq
- Market Cap
- IMNM 747.7M
- CELC 612.8M
- IPO Year
- IMNM 2020
- CELC 2017
- Fundamental
- Price
- IMNM $12.09
- CELC $15.45
- Analyst Decision
- IMNM Strong Buy
- CELC Strong Buy
- Analyst Count
- IMNM 4
- CELC 6
- Target Price
- IMNM $28.75
- CELC $29.17
- AVG Volume (30 Days)
- IMNM 761.5K
- CELC 289.7K
- Earning Date
- IMNM 11-07-2024
- CELC 11-11-2024
- Dividend Yield
- IMNM N/A
- CELC N/A
- EPS Growth
- IMNM N/A
- CELC N/A
- EPS
- IMNM N/A
- CELC N/A
- Revenue
- IMNM $10,784,000.00
- CELC N/A
- Revenue This Year
- IMNM N/A
- CELC N/A
- Revenue Next Year
- IMNM N/A
- CELC N/A
- P/E Ratio
- IMNM N/A
- CELC N/A
- Revenue Growth
- IMNM 62.73
- CELC N/A
- 52 Week Low
- IMNM $6.93
- CELC $9.36
- 52 Week High
- IMNM $30.96
- CELC $22.19
- Technical
- Relative Strength Index (RSI)
- IMNM 36.69
- CELC 52.95
- Support Level
- IMNM $11.81
- CELC $14.06
- Resistance Level
- IMNM $12.44
- CELC $15.57
- Average True Range (ATR)
- IMNM 0.68
- CELC 0.62
- MACD
- IMNM -0.11
- CELC 0.17
- Stochastic Oscillator
- IMNM 11.61
- CELC 66.87
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.